Terms: = Thyroid cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Treatment
161 results:
1. Regulatory T cells as crucial trigger and potential target for hyperprogressive disease subsequent to PD-1/pd-l1 blockade for cancer treatment.
Ren Z; Yang K; Zhu L; Yin D; Zhou Y
Int Immunopharmacol; 2024 May; 132():111934. PubMed ID: 38574701
[TBL] [Abstract] [Full Text] [Related]
2. Chronic Lymphocytic thyroiditis with Oncocytic Metaplasia Influences pd-l1 Expression in Papillary thyroid Carcinoma.
Santana VB; Krüger VM; Abrahão MCY; Cantú PLM; Brackmann RL; Pandolfi GM; Marisco LS; Remonatto G; Ferreira LA; Graudenz MS
Head Neck Pathol; 2024 Mar; 18(1):14. PubMed ID: 38457034
[TBL] [Abstract] [Full Text] [Related]
3. K48-linked deubiquitination of VGLL4 by USP15 enhances the efficacy of tumor immunotherapy in triple-negative breast cancer.
Wang X; Deng X; Hu J; Zheng W; Ye D; Zhou X; Fang L
Cancer Lett; 2024 Apr; 588():216764. PubMed ID: 38431034
[TBL] [Abstract] [Full Text] [Related]
4. First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study.
Soll D; Bischoff P; Frisch A; Jensen M; Karadeniz Z; Mogl MT; Horst D; Penzkofer T; Spranger J; Keilholz U; Mai K
BMC Endocr Disord; 2024 Feb; 24(1):25. PubMed ID: 38383419
[TBL] [Abstract] [Full Text] [Related]
5. Mendelian randomization study highlights hypothyroidism as a causal determinant of alopecia areata.
Zheng XY; Ma YP; Zhang B; Chen YX; Tang L; Tai XH; Cao JH
Front Endocrinol (Lausanne); 2023; 14():1309620. PubMed ID: 38292771
[TBL] [Abstract] [Full Text] [Related]
6. Predictive biomarkers for immune-related adverse events in cancer patients treated with immune-checkpoint inhibitors.
Wang J; Ma Y; Lin H; Wang J; Cao B
BMC Immunol; 2024 Jan; 25(1):8. PubMed ID: 38267897
[TBL] [Abstract] [Full Text] [Related]
7. Characteristics and immune checkpoint status of radioiodine-refractory recurrent papillary thyroid carcinomas from Ukrainian Chornobyl Tissue Bank donors.
Bogdanova T; Rogounovitch TI; Zurnadzhy L; Mitsutake N; Tronko M; Ito M; Bolgov M; Chernyshov S; Gulevatyi S; Masiuk S; Yamashita S; Saenko VA
Front Endocrinol (Lausanne); 2023; 14():1343848. PubMed ID: 38260161
[TBL] [Abstract] [Full Text] [Related]
8. Immunotherapy for endocrine tumours: a clinician's perspective.
Angelousi A; Tzoulis P; Tsoli M; Chatzellis E; Koumarianou A; Kaltsas G
Endocr Relat Cancer; 2024 Apr; 31(4):. PubMed ID: 38235757
[TBL] [Abstract] [Full Text] [Related]
9. Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial.
Jiang Z; Ouyang Q; Sun T; Zhang Q; Teng Y; Cui J; Wang H; Yin Y; Wang X; Zhou X; Wang Y; Sun G; Wang J; Zhang L; Yang J; Qian J; Yan M; Liu X; Yi T; Cheng Y; Li M; Zang A; Wang S; Wang C; Wu X; Cheng J; Li H; Lin Y; Geng C; Gu K; Xie C; Xiong H; Wu X; Yang J; Li Q; Chen Y; Li F; Zhang A; Zhang Y; Wu Y; Nie J; Liu Q; Wang K; Mo X; Chen L; Pan Y; Fu P; Zhang H; Pang D; Sheng Y; Han Y; Wang H; Cang S; Luo X; Yu W; Deng R; Yang C; Keegan P
Nat Med; 2024 Jan; 30(1):249-256. PubMed ID: 38191615
[TBL] [Abstract] [Full Text] [Related]
10. Novel dual inhibitors of PARP and HDAC induce intratumoral STING-mediated antitumor immunity in triple-negative breast cancer.
Zhu Q; Dai Q; Zhao L; Zheng C; Li Q; Yuan Z; Li L; Xie Z; Qiu Z; Huang W; Liu G; Zu X; Chu B; Jiang Y
Cell Death Dis; 2024 Jan; 15(1):10. PubMed ID: 38182579
[TBL] [Abstract] [Full Text] [Related]
11. Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma.
Afaq F; Agarwal S; Bajpai P; Diffalha SA; Kim HG; Peter S; Khushman M; Chauhan SC; Mukherjee P; Varambally S; Manne U
Neoplasia; 2024 Jan; 47():100951. PubMed ID: 38039923
[TBL] [Abstract] [Full Text] [Related]
12. Boosted abscopal effect from radiotherapy and pembrolizumab in anaplastic thyroid cancer: a mini-review and case report.
Goh D; Lim KH; Sudirman SRB; Ang MK; Chua MLK; Lim CM
Chin Clin Oncol; 2023 Oct; 12(5):57. PubMed ID: 37964542
[TBL] [Abstract] [Full Text] [Related]
13. Pembrolizumab combined with anlotinib improves therapeutic efficacy in pulmonary sarcomatoid carcinoma with TMB-H and pd-l1 expression: a case report and literature review.
Wu S; Wu S; Liao X; Zhou C; Qiu F; Wang C; Zhong W
Front Immunol; 2023; 14():1274937. PubMed ID: 37936698
[TBL] [Abstract] [Full Text] [Related]
14. Intrathyroid thymic carcinoma: A clinicopathological analysis of 22 cases.
Gao Y; Pan Y; Luo Y; Cheng R; Zhai Q
Ann Diagn Pathol; 2023 Dec; 67():152221. PubMed ID: 37925863
[TBL] [Abstract] [Full Text] [Related]
15. Network Pharmacological Analysis and Experimental Validation of the Effects of Silybin on Proliferation, Migration, and Immunotherapy of Papillary thyroid cancer.
Xie W; Li H; Lin Q; Ke N
Endocr Metab Immune Disord Drug Targets; 2024; 24(6):672-690. PubMed ID: 37855349
[TBL] [Abstract] [Full Text] [Related]
16. Toxicity spectrum and risk factors for chemo-immunotherapy in locally advanced or metastatic lung cancer.
Li J; Shi W; Xiong J; Huang Y; He Y; Zhou Y; Yang Z; Peng Y
Clin Exp Immunol; 2023 Dec; 214(2):162-169. PubMed ID: 37696500
[TBL] [Abstract] [Full Text] [Related]
17. Endocrine immune-related adverse effects of immune-checkpoint inhibitors.
Trevisani V; Iughetti L; Lucaccioni L; Predieri B
Expert Rev Endocrinol Metab; 2023; 18(5):441-451. PubMed ID: 37682107
[TBL] [Abstract] [Full Text] [Related]
18. Ononin Relieves the thyroid cancer Progression through Targeting the Caspase 3 and cd274 Expression Levels.
Du L; Zeng D; Hu X; Ren X; He D
Biol Pharm Bull; 2023; 46(8):1041-1048. PubMed ID: 37532555
[TBL] [Abstract] [Full Text] [Related]
19. STAT3 inhibition enhances gemcitabine sensitivity in pancreatic cancer by suppressing EMT, immune escape and inducing oxidative stress damage.
Guo H; Hu Z; Yang X; Yuan Z; Gao Y; Chen J; Xie L; Chen C; Guo Y; Bai Y
Int Immunopharmacol; 2023 Oct; 123():110709. PubMed ID: 37515849
[TBL] [Abstract] [Full Text] [Related]
20. RNA Sequencing Reveals Unique Transcriptomic Signatures of the thyroid in a Murine Lung cancer Model Treated with PD-1 and pd-l1 Antibodies.
Pollack R; Stokar J; Lishinsky N; Gurt I; Kaisar-Iluz N; Shaul ME; Fridlender ZG; Dresner-Pollak R
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445704
[TBL] [Abstract] [Full Text] [Related]
[Next]
